This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (17)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Statistics and Research Methods  • Photosensitivity Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

The VA Topical Tretinoin Chemoprevention (VATTC) Trial

Martin A. Weinstock, MD, PhD; Stephen F. Bingham, PhD; Gary W. Cole, MD; David Eilers, MD; Mark F. Naylor, MD; James Kalivas, MD; J. Richard Taylor, MD; Hayes B. Gladstone, MD; Daniel J. Piacquadio, MD; John J. DiGiovanna, MD

Arch Dermatol. 2001;137:1055-1058.

Objective  To assess the reliability of counts of actinic keratoses (AKs) and the effect of a brief joint discussion of discrepancies on that reliability.

Design and Intervention  Seven dermatologists independently counted AKs on the face and ears before and after a brief joint discussion of discrepancies.

Setting and Patients  A volunteer sample of 9 patients from the ongoing VA (Department of Veterans Affairs) Topical Tretinoin Chemoprevention (VATTC) Trial. All participating individuals are veterans and have had 2 or more keratinocyte carcinomas (basal or squamous cell carcinoma) in the 5 years before enrollment in the study.

Main Outcome Measure  Standard deviation of estimates of the Poisson regression parameter for the dermatologists.

Results  Substantial variation was found among the dermatologists in their AK counts. The SD of the parameter estimates for the dermatologists decreased from 0.45 to 0.24 after the brief joint discussion, a 47% decrease (P = .076). The variation attributable to the dermatologists also decreased substantially (²₆ decrease, 94 to 12).

Conclusions  Actinic keratoses are common, and there is a continuous spectrum of lesions that ranges from sun-damaged skin to squamous cell carcinoma in situ. Clinical distinguishing features may be difficult to delineate precisely. Counts of AK are commonly performed, but appear to be unreliable, even when performed by experienced dermatologists. Joint discussion of discrepancies may enhance the reliability of these counts, although substantial variation remains. Research that relied on these counts must be reevaluated in light of the marked variation among expert observers. Future studies should consider measures to assess and enhance reliability.

From the Dermatoepidemiology Unit, Veterans Affairs (VA) Medical Center, Providence (Dr Weinstock), and Department of Dermatology, Rhode Island Hospital and Brown University, Providence (Drs Weinstock and DiGiovanna); the VA Cooperative Studies Program Coordinating Center, Perry Point, Md (Dr Bingham); Department of Dermatology, VA Medical Center Long Beach, Long Beach, Calif (Dr Cole); Department of Dermatology, University of California–Irvine (Dr Cole); Division of Dermatology, Hines VA Medical Center, Hines, Ill (Dr Eilers); Division of Dermatology, Loyola University, Chicago, Ill (Dr Eilers); Department of Dermatology, VA Medical Center Oklahoma City and University of Oklahoma, Oklahoma City (Dr Naylor); Department of Dermatology, Carl T. Hayden VA Medical Center and University of Arizona, Phoenix (Dr Kalivas); Department of Dermatology, University of Miami, and Dermatology Service, Miami VA Medical Center, Miami, Fla (Dr Taylor); Department of Dermatology, VA Medical Center West Los Angeles, Los Angeles, Calif (Dr Gladstone); and Department of Dermatology, University of California–San Diego (Dr Piacquadio). Dr Gladstone is now affiliated with the Division of Dermatologic Surgery, Stanford University, Stanford, Calif.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2001;137(8):1122-1123.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Topical Fluorouracil for Actinic Keratoses and Photoaging: A Clinical and Molecular Analysis
Sachs et al.
Arch Dermatol 2009;145:659-666.
ABSTRACT | FULL TEXT  

Association Between Statin Use and Risk for Keratinocyte Carcinoma in the Veterans Affairs Topical Tretinoin Chemoprevention Trial
Dore et al.
ANN INTERN MED 2009;150:9-18.
ABSTRACT | FULL TEXT  

Clinical Recognition of Actinic Keratoses in a High-Risk Population: How Good Are We?
Venna et al.
Arch Dermatol 2005;141:507-509.
ABSTRACT | FULL TEXT